March 7, 2022 -- Felix Biotechnology received a strategic investment from the Cystic Fibrosis Foundation as part of a Therapeutics Development Award. The award will bolster Felix's work on creating a novel therapy to manage chronic Pseudomonas aeruginosa lung infections.
The company said that its phage therapies are specially designed to consider and drive advantageous evolutionary outcomes of phage treatment, resulting in a more durable therapy.
The therapy is currently being evaluated in a clinical trial at Yale University. Felix's discovery and engineering technology platforms are built on technology from Yale and Lawrence Berkeley National Laboratory.